Literature DB >> 9420225

Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry.

T Dragic1, A Trkola, S W Lin, K A Nagashima, F Kajumo, L Zhao, W C Olson, L Wu, C R Mackay, G P Allaway, T P Sakmar, J P Moore, P J Maddon.   

Abstract

The CC-chemokine receptor CCR5 is required for the efficient fusion of macrophage (M)-tropic human immunodeficiency virus type 1 (HIV-1) strains with the plasma membrane of CD4+ cells and interacts directly with the viral surface glycoprotein gp120. Although receptor chimera studies have provided useful information, the domains of CCR5 that function for HIV-1 entry, including the site of gp120 interaction, have not been unambiguously identified. Here, we use site-directed, alanine-scanning mutagenesis of CCR5 to show that substitutions of the negatively charged aspartic acid residues at positions 2 and 11 (D2A and D11A) and a glutamic acid residue at position 18 (E18A), individually or in combination, impair or abolish CCR5-mediated HIV-1 entry for the ADA and JR-FL M-tropic strains and the DH123 dual-tropic strain. These mutations also impair Env-mediated membrane fusion and the gp120-CCR5 interaction. Of these three residues, only D11 is necessary for CC-chemokine-mediated inhibition of HIV-1 entry, which is, however, also dependent on other extracellular CCR5 residues. Thus, the gp120 and CC-chemokine binding sites on CCR5 are only partially overlapping, and the former site requires negatively charged residues in the amino-terminal CCR5 domain.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9420225      PMCID: PMC109374     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  49 in total

1.  Multiple extracellular elements of CCR5 and HIV-1 entry: dissociation from response to chemokines.

Authors:  R E Atchison; J Gosling; F S Monteclaro; C Franci; L Digilio; I F Charo; M A Goldsmith
Journal:  Science       Date:  1996-12-13       Impact factor: 47.728

2.  The HIV coreceptors CXCR4 and CCR5 are differentially expressed and regulated on human T lymphocytes.

Authors:  C C Bleul; L Wu; J A Hoxie; T A Springer; C R Mackay
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

3.  Role of the first and third extracellular domains of CXCR-4 in human immunodeficiency virus coreceptor activity.

Authors:  A Brelot; N Heveker; O Pleskoff; N Sol; M Alizon
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

4.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

5.  Role of the amino-terminal extracellular domain of CXCR-4 in human immunodeficiency virus type 1 entry.

Authors:  L Picard; D A Wilkinson; A McKnight; P W Gray; J A Hoxie; P R Clapham; R A Weiss
Journal:  Virology       Date:  1997-04-28       Impact factor: 3.616

6.  Human immunodeficiency virus strains differ in their ability to infect CD4+ cells expressing the rat homolog of CXCR-4 (fusin).

Authors:  O Pleskoff; N Sol; B Labrosse; M Alizon
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

7.  Resistance to HIV-1 infection in caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene.

Authors:  M Samson; F Libert; B J Doranz; J Rucker; C Liesnard; C M Farber; S Saragosti; C Lapoumeroulie; J Cognaux; C Forceille; G Muyldermans; C Verhofstede; G Burtonboy; M Georges; T Imai; S Rana; Y Yi; R J Smyth; R G Collman; R W Doms; G Vassart; M Parmentier
Journal:  Nature       Date:  1996-08-22       Impact factor: 49.962

8.  Inhibition of human immunodeficiency virus fusion by a monoclonal antibody to a coreceptor (CXCR4) is both cell type and virus strain dependent.

Authors:  A McKnight; D Wilkinson; G Simmons; S Talbot; L Picard; M Ahuja; M Marsh; J A Hoxie; P R Clapham
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

9.  CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro.

Authors:  L Wu; W A Paxton; N Kassam; N Ruffing; J B Rottman; N Sullivan; H Choe; J Sodroski; W Newman; R A Koup; C R Mackay
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

10.  Change in coreceptor use correlates with disease progression in HIV-1--infected individuals.

Authors:  R I Connor; K E Sheridan; D Ceradini; S Choe; N R Landau
Journal:  J Exp Med       Date:  1997-02-17       Impact factor: 14.307

View more
  88 in total

1.  A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5.

Authors:  T Dragic; A Trkola; D A Thompson; E G Cormier; F A Kajumo; E Maxwell; S W Lin; W Ying; S O Smith; T P Sakmar; J P Moore
Journal:  Proc Natl Acad Sci U S A       Date:  2000-05-09       Impact factor: 11.205

2.  Oligomeric modeling and electrostatic analysis of the gp120 envelope glycoprotein of human immunodeficiency virus.

Authors:  P D Kwong; R Wyatt; Q J Sattentau; J Sodroski; W A Hendrickson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

3.  Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains.

Authors:  A L Edinger; C Blanpain; K J Kunstman; S M Wolinsky; M Parmentier; R W Doms
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes.

Authors:  E G Cormier; D N Tran; L Yukhayeva; W C Olson; T Dragic
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

5.  Apelin, the natural ligand of the orphan seven-transmembrane receptor APJ, inhibits human immunodeficiency virus type 1 entry.

Authors:  M Cayabyab; S Hinuma; M Farzan; H Choe; S Fukusumi; C Kitada; N Nishizawa; M Hosoya; O Nishimura; T Messele; G Pollakis; J Goudsmit; M Fujino; J Sodroski
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

6.  Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding.

Authors:  Stéphane Basmaciogullari; Gregory J Babcock; Donald Van Ryk; Woj Wojtowicz; Joseph Sodroski
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

7.  Structure modeling of the chemokine receptor CCR5: implications for ligand binding and selectivity.

Authors:  M Germana Paterlini
Journal:  Biophys J       Date:  2002-12       Impact factor: 4.033

8.  The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor.

Authors:  Emmanuel G Cormier; Tatjana Dragic
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Structural and functional characterization of the human CCR5 receptor in complex with HIV gp120 envelope glycoprotein and CD4 receptor by molecular modeling studies.

Authors:  Shuqun Liu; Shixiu Fan; Zhirong Sun
Journal:  J Mol Model       Date:  2003-08-29       Impact factor: 1.810

10.  Tyrosine sulfation of CCR5 N-terminal peptide by tyrosylprotein sulfotransferases 1 and 2 follows a discrete pattern and temporal sequence.

Authors:  Christoph Seibert; Martine Cadene; Anthony Sanfiz; Brian T Chait; Thomas P Sakmar
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-08       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.